Abstract OBJECTIVE: The Synergy ® system, a miniature partial circulatory support device, is implanted with an off-pump, minimally invasive surgical approach. In our experience, implantation of this system is associated with fewer perioperative adverse events than current full support devices. This approach therefore offers the possibility of treating elderly chronic heart-failure patients who might not ordinarily be considered for long-term circulatory support.
INTRODUCTION
Use of left ventricular assist devices (LVADs) for treating end-stage heart failure is becoming increasingly accepted among the surgical and cardiology community worldwide. There have been major advances, particularly recently, in improving device durability. However, because LVAD implantation requires a relatively major surgery (sternotomy, cardiopulmonary bypass (CPB)) that is associated with significant risks of severe adverse events, LVAD use is still generally restricted to the most critically ill patients with a short life expectancy. In such patients, the benefits, in terms of improved survival to transplant and, when used as 'destination therapy' (DT), improved overall survival have been demonstrated [1] .
We previously introduced the CircuLite ® Synergy ® Pocket Micro-pump (CircuLite, Inc., Saddle Brook, NJ, USA), which is a small (AA battery-sized) blood pump that is implanted with an off-pump, right-sided minithoracotomy procedure [2, 3] . The device pumps blood from the left atrium to the right subclavian artery at a maximum rate of 4.25 l/min. As such, the device provides partial haemodynamic support; that is, part of the blood flow is provided by native heart function. The fundamental concept is that implantation of a smaller device requiring a less-invasive surgery would justify its use in patients who are slightly less sick or more fragile than those currently receiving LVADs.
Haemodynamic and clinical effects of this device obtained from a pre-CE mark European trial have been reported previously. From those data, we compared the beneficial and adverse effects in the subgroup of patients with age ≥70 years with those in patients who were <70 years old.
PATIENTS AND METHODS
The CircuLite Synergy device has been studied in a multicentre study in Europe involving the University of Leuven, Belgium; the Istituto Clinico Humanitas in Rozzano (Mi); the Hannover Medical School, Hannover, Germany; the University of Muenster, Germany; the University of Cologne, Germany and the University of Freiburg, Germany, The National Institute of Cardiovascular Diseases Bratislava, Slovak Republic and the Harefield NHS Hospital, Middlesex, UK.
Inclusion criteria for the trial included: age between 18 and 75 years; eligibility for cardiac transplant, exclusion for no reason other than age; New York Heart Association Class (NYHA) III or IV and with self-reported poor quality of life despite appropriate treatment with diuretics, angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blockade and β-blocker as tolerated; being ambulatory and able to perform a 6-min walk test and metabolic stress test; patient should not be continuously inotrope dependent.
Exclusion criteria included: acute decompensated heart failure, acute post-cardiotomy heart failure, existing thrombus in the left atrium, mechanical mitral or aortic valve, significant aortic regurgitation, severe depressed renal function (serum creatinine > 2.5 mg dl −1 ), elevated liver enzymes >2 times the upper limit of normal, and contraindication to anticoagulation.
The preoperative evaluation also included a right-heart catheterization, a transthoracic echocardiography and spiroergometry. These data were presented to an independent clinical review committee (CRC) composed of 2 heart-failure surgeons and 1 heart-failure cardiologist. The purpose of the CRC was to ensure, to the extent possible from a review of clinical data, that the patient was not 'too sick' to potentially derive clinical benefit from partial support and that there were no unforeseen contraindications for implantation.
The Synergy device has been described previously ( Fig. 1 ) [2] . In brief, the pump is the size of an AA battery, weighing 25 g and having an outer body diameter of 14 mm and a length of 49 mm. The pump has a magnetically stabilized, hydrodynamically levitated rotor that spins at 20 000-28 000 rpm. The inflow cannula is made of silicone reinforced with nitinol with a length of 20.5 cm and an inner diameter of 6 mm and has a Dacron cuff on the tip made of titanium to enhance healing. The outflow graft is a 1-mm thick polytetrafluoroethylene (PTFE) prosthesis with an inner diameter of 8 mm and is trimmed to fit during the implant. A percutaneous lead connects the micropump to a rechargeable dual battery pack system and controller.
The surgical implant procedure has also been described previously [2] . In brief, after induction of anaesthesia, an 4 cm subclavicular incision is made and the right subclavian artery is isolated. A subcutaneous pocket is formed anterior to the right pectoralis muscle similar to a pacemaker pocket. Thereafter, a 10-cm anterolateral thoracotomy in the fourth right intercostal space is performed. The pericardium is opened with respect to the phrenic nerve, and two 4/0 polypropylene purse-string sutures are placed in the left atrium between the insertions of the right upper and lower pulmonary veins. The micro-pump percutaneous lead is then tunnelled to exit the body over the right upper quadrant of the abdomen. After partial heparinization (100 IU/kg to obtain ACT of >250 s) a guidewire is inserted thought the purse-strain, the nitinol-reinforced silicone-inflow cannula is inserted on a trocar over the guidewire using the Seldinger technique and secured with the two purse-string sutures. Transoesophageal echo is used throughout the procedure to confirm appropriate positioning. The proximal end of the inflow cannula is tunnelled through the second intercostal space to exit the thorax in the area of the subcutaneous pocket. The micro-pump is then tested and the PTFE outflow graft is sized to the proper length and anastomosed to the subclavian artery. The micro-pump is deaired retrograde via the subclavian artery and the inflow cannula is connected to the pump. After insertion of a chest tube and drain in the pump pocket, the wounds are closed in layers.
Patients were anticoagulated with aspirin (100 mg/day) and warfarin with the aim of achieving an international normalized ratio (INR) value of 2.5-3.0.
Statistics
Descriptive statistics are used to summarize data with the results expressed as means with standard deviations, unless otherwise noted. Comparison of data between time points was made with paired t-tests. All calculations were performed with Microsoft Excel.
This study was conducted following the Declaration of Helsinki and approval was given by all local institutional human research and ethics committees. All the patients provided informed consent to participate in this study.
RESULTS

Patient characteristics
This study included data from 54 patients (12 patients >70 years) enrolled in the Synergy system trial. Patient baseline characteristics are summarized in Table 1 . Of note, body surface area (BSA) was significantly lower in the older patients. In addition, pulmonary pressures were slightly lower in the older patients.
However, baseline echocardiographic and exercise tolerance tests were similar, with a low peak VO 2 values in both groups (10.8 ± 3.1 vs 11.1 ± 2.1 in younger vs elderly).
Lab assessment for end organ function showed difference between groups only for renal function, with a nearly significant difference in creatinine and significantly increased BUN (59 ± 33 vs 91 ± 38) and eGFR (71 ± 23 vs 50 ± 38) in the older group. Haemodynamics Young <70 years (mean ± SD) (n = 25) Elderly ≥70 years (mean ± SD) (n = 6) Baseline Follow-up Δ Baseline Follow-up Δ MAP 76 ± 9 80 ± 10 4 ± 13 78 ± 13 82 ± 13 3 ± 25 CVP 14 ± 7 10 ± 4 −4 ± 6 11 ± 6 10 ± 7 −1.5 ± 10 PAPm 39 ± 10 28 ± 7 −11 ± 10 34 ± 17 30 ± 8 −4 ± 20 PCWP 28 ± 8 18 ± 6 −10 ± 8 25 ± 16 16 ± 8 −9 ± 16 CI 2.2 ± 0.6 2.7 ± 0.6 0.5 ± 0.6 2 ± 0. Finally, baseline haemoglobin was also slightly lower in older vs younger patients (12.6 ± 1.9 vs 11.3 ± 1.3 P = 0.055).
The main difference between the groups was in baseline therapies. The older patients had a greater proportion with implantable cardioverter-defibrillators, 74 vs 100% and cardiac resynchronization therapy, 29 vs 83% indicating that the older patients had a greater tendency to be treated with all possible device therapies prior to considering VAD therapy. In contrast, there was decreased use of medical therapies: β-blockers, 88 vs 67%; ACE inihibitors, 64 vs 33%; angiotensin receptor blockers, 14 vs 8%. This suggests that older patients were less likely to tolerate these drugs.
Haemodynamic effects
Haemodynamic parameters were measured at baseline for each patient. Paired haemodynamic data ( pre-and postimplant) were available for 6 patients in the elderly group after a median of 18 weeks and for 25 patients in the young group after a median of 22 weeks. The results are summarized in Table 2 .
As expected, given the lower level of baseline pulmonary haemodynamic impairment, in the elder group the magnitude of haemodynamic improvement was less compared with the younger group (PAP −11 ± 10 mmHg difference in the younger compared with −4 ± 20 mmHg drop in the elderly) despite similar drops in the pulmonary capillary wedge pressure (PCWP) (−10 ± 8 mmHg vs −9 ± 16 mmHg). Other parameters were similar at baseline and during follow-up. Table 3 summarizes the results of exercise testing in the two groups at baseline and follow-up.
Exercise tolerance
As summarized, the degree of improvement in peak VO 2 , exercise duration and 6-min walk test tended to be less in the elderly patients compared with the younger patients.
Major adverse events
Major adverse events, which were classified and reported according to INTERMACS definitions, are summarized in Table 4 . In the table, we report incidence of complication expressed as patient/year of support, and prevalence in the population as percentage of patient suffering the complication. The most frequent major complication was bleeding, which occurred in 38% of young patients and in 75% of elderly patients; however, the overall event rate being fairly comparable (0.93 vs 1.06 P = ns). Most of these events were perioperative with a large proportion of patients requiring intra-and postoperative blood transfusions or reoperation. Infection was the second most frequent complication. These were more often driveline related in the younger population, probably due to the more active lifestyle. In comparison, the elderly patients were more likely to have systemic infections, probably due to a reduced multisystem functional reserve. However, it is noteworthy that there has never been the need to remove a device because of an infection-related complication.
With the relatively small sample size, none of the differences in the rates of adverse events was significant.
Patient outcome
The study spanned >5 years, during which time both the Synergy device and surgical implant technique evolved to address adverse outcomes along the way. In total, the device underwent three major improvements. Thus, overall adverse event rates and clinical outcomes improved significantly along the way. Nevertheless, the overall patient outcomes from the trial are summarized in Table 5 . It can be seen that the two patient groups were implanted with a different intention to treat: the average length of support in the younger was 188 days (mostly bridge to transplant or bridge to decision), almost doubled (337 days) in the elderly, with 5 patients that passed 1 year of support (destination therapy). None of the elderly underwent transplant, while 2 patients underwent device explant (1 device upgrade and 1 because of patient's withdrawal). It should be noted that the high rate of device upgrade in the young group was mainly due to the initial experience with the device (Device Version 1-3), when device thrombosis had not been completely addressed and device upgrade to a full VAD was sometimes preferred to a Synergy ® replacement.
DISCUSSION
The Synergy device was designed with the purpose of providing a small, minimally invasive implantable assist device that would benefit patients with severe symptomatic heart failure with no other treatment option, who are not yet sick enough to justify implantation of a full-support ventricular support device. The initial experience and magnitude of adverse events has suggested that the minimally invasive implant procedure might be well tolerated by older and more fragile patients, specifically, more tolerable than a full sternotomy on CPB procedure. This was the rationale for expanding the indications of the current study to include older patients. Clinically, older patients have certain characteristics that differ from those of the younger patients. First, they usually have a longer history of heart failure. In most cases, the elderly are not eligible for transplant, and thus have already undergone more intensive efforts to exhaust all conventional therapies and have identified themselves as non-responders. Furthermore, elderly patients tend to recover and rehabilitate more slowly from surgery. They are generally are more prone to infection and other complications. Bleeding might be an issue due to particular tissue frailty of the elderly patient.
Despite its limited experience for this class of patient [4] and early clinical experiences with the device [2, 3, 5] , it was hypothesized that when applied prior to significant end-organ dysfunction and becoming inotrope dependent, partial support with the Synergy device can indeed provide adequate support and interrupt the progressive haemodynamic deterioration characteristic of severe heart failure. In particular, the lesser invasive nature of this system (small size, no sternotomy, and no CPB) can be considered to be associated with less adverse events in the short-and long-term, especially in more fragile patients. This strategy may be particularly useful in elderly patients less likely to be able to tolerate more invasive procedures.
The patients studied were ambulatory on the transplant waiting list with severe symptomatic heart failure but preserved end-organ function who were not chronically inotropic dependent, and thus generally not considered for LVAD implant. Although not uncommonly, this group of patients deteriorates over a relatively short period of time to the point at which they exhibit renal dysfunction, increasing fatigability and dyspnoea.
In this paper we selected, out of the overall trial, a group of patient older than 70 years and we compared them for baseline characteristics and outcome with the younger, standard LVAD population. As expected, it was confirmed that the elder population had undergone a longer and more exhausting course of heart-failure disease, experiencing all the armamentarium available for heart failure cardiologists. Overall, the level of symptom tolerance is better than in a younger population (as testified by a lower NYHA class) despite a similar function performance at the walking or cardiopulmonary tests. Part of this better tolerance of heart-failure symptoms can be probably due to a lower state of congestion as testified by lower PCWP and subsequently a lower pulmonary arterial pressure, significantly lower compared with the younger population studied. Despite these minor differences, when we focused on the haemodynamic efficacy of the mechanical support we did not see any difference comparing the two populations we studied.
As expected, the renal function in the elder population is significantly more compromised, although this did not really affect the outcome resulting neither in a higher rate of acute failure post-operatively nor in the long run of chronic support.
When we examine the functional data, the elderly report the same advantages from the partial support as the younger. The average improvement in peak VO 2 and increase at the 6-min walking test are similar and comparable between the two cohorts. Furthermore the elderly, despite a lower expected functional reserve, reported a higher ability to adapt to LVAD support regarding the carrying of a complete battery pack and controller; although the elderly generally preferred the lighter battery (380 g for average 4 h use) provided by CircuLite that ensured a shorter duration for a lighter weight compared with the standard (645 g for 8 h duration). The ultimate use of the Synergy system is a permanent implant in patients who do not qualify for heart transplant or have a very long expected wait time for a donor organ or in whom another sternotomy would be too difficult because of previous cardiac operations. The results of the present study suggests that heart-failure state can be improved and stabilized by a device as small as Synergy pumping up to 4.25 l/min. The elective off-pump implantation procedure performed through a minithoracotomy was well tolerated in the elderly. Infections related to the device or driveline also were limited in the elderly and more fragile population, to a rate comparable with that in the younger population.
The overall rate of adverse events is comparable throughout the study population, not showing any trend across aging classes, apart from small trends in more bleeding events, a wellknown complication of surgery in the elderly.
Survival rates at follow-up are comparable, and the longer average support in the elderly is clearly proofing the efficacy of this device in this delicate population and the feasibility of longterm support and destination therapy in septuagenarians.
Collectively, these findings set the stage for expanding study of this device in long-term applications, including elderly nontransplant candidates.
APPENDIX. CONFERENCE DISCUSSION
Dr A. Loforte (Bologna, Italy): A few concerns. The Synergy® device provides partial haemodynamic support, as you said, and its usage is associated with improved haemodynamics, thus appearing to reverse the deterioration of end-stage heart failure.
Given that the main goal of Synergy® support, is towards an early implantation of the system in patients at a high INTERMACS level, what about myocardial recovery and explantation of the device? What is your policy on that? Did you have any patients, or I mean, in your opinion a particular kind of population to be implanted?
Your manuscript shows that you offered the device to an old population, destination therapy, but the average time of support is still limited. What about any company plan concerning an alternating speed algorithm to make sure that the pump is well washed out? You show that you are using it. This may help to achieve more durability of the pump. Is this the most important issue in your opinion?
And then the third question. You had a high rate of bleeders. Even 38% in young patients is not so low. Did you have any right ventricular failure event related to transfusions even if the partial support decreases the risk? And in the case of RVF, which kind of treatment -pharmacological or mechanical treatment?
Dr Barbone: This is a compendium on VADs that I am asked to approach now. So if I can remember the questions: recovery, I personally do not believe in recovery, but this is just a feeling. I cannot speak for the company. I think that if we do not approach the aetiology of heart failure -loss of mass in ischaemic or some genetic issue in dilated, or what we call idiopathicthat itself means we do not know the diagnosis, then I do not think we can talk about recovery. We know that in myocarditis, where there is an inflammation of some kind, once the inflammation is gone, we have recovery.
So is earlier implantation of the device feasible? Yes. Is this going to trigger recovery? I personally do not know. I think we can slow the deterioration of the patient, and of the myocardium especially, because this patient goes to full medical support. And we know from many cardiology trials that beta blockers, ACE inhibitors, antihormonal drugs, slow down the deterioration of the remaining myocardium. I do not think we are going to go through a full recovery intended as "healing the heart" unless we really address, it is my feeling, unless we address the aetiology of the disease. And this means, obviously, either giving more myocardium if there is a loss of myocardium, or genetically to somehow repair the diseases behind the failure.
Regarding the destination therapy, durability of the device, I think it is durable. I have not known from the database any worn-out devices. Obviously bench tests are going over five years, but you should ask the company more about this. I know that in case the device wears out and we are to approach this, device replacement is very easy. It takes 30 minutes. We had to go through a device replacement ourselves because of a technical issue; we had a surgical issue. It took 30 minutes. The patient did not even go through the ICU. He came from the ward. We replaced the device. We do not go to local anaesthesia because we are not that keen, but we replaced the device in 30 minutes, and we sent the patient directly to the ward, extubating him in the OR. So I think that even if the device is going to last only three years, we can exchange the device safely in the short term, and this cannot be a concern.
Dr Loforte: I think the goal should be the durability of the pump, not the intermittent exchange of the pump.
Dr Barbone: I think durability at five years is achievable. I think three years is reasonable. I think three years is decent durability. I do not have data to tell that it is going to be longer. Our longest patient is going to hit the two-year point with the same pump since the implant on November 30th. So it is going to be the same pump without apparently any major wear from the implant that we have. Obviously we are going to examine the pump if we need to. But so far two years, and no problem with the same device ongoing. This is my experience. It is a young trial; we'll see in the future. But in any case, I think it can be easily approached.
You asked about bleeding; bleeding is an issue. We have gone through that problem. We think that every device is a device: either it is small or it is large, the pump, surface, interface, speed, shear stress, whatever you want to call it, is going to affect coagulation. We have some interesting data that have been collected in Leuven where they compared different devices, and they looked, for example, at the Von Willebrand factor. We see that Circulite® affects the Von Willebrand factor, as does HeartWare® or Thoratec®. I do not have the actual data, but I have the feeling that any device is going to affect the coagulation pretty similarly. These patients are obviously more fragile. We all operate on older patients. We know they bleed more. They are going to pay the price.
Dr G. Gerosa (Padova, Italy): I have a question regarding the death rate of 50% in the elderly population. Do you think that death is -you did not give us the cause of death, so maybe that is the answer. So do you think that if you did not use a partial support in those patients, let's say full support, the death rate would decrease, or does it have nothing to do with it?
Dr Barbone: No. None of the deaths were heart failure related. We had death for bleeding on the seventh postop day. The patient was on the ward and in shock, and he had a complete haemothorax. We do not have data. The number is very small, obviously. We are talking about six patients. But none of them was because of deteriorating heart failure.
The explant lVAD/death rate is due to an inefficient support because some of the patients were not doing well enough or there were some problems. But the partial support has been proven pretty effective in this kind of population, and the death rate is not affected.
Dr A. Wahba (Trondheim, Norway): You showed us or explained to us that the functional recovery of the patients was good, but the VO 2 max data that you showed, they were almost similar from 11 to 12. Is there so little gain in these patients with this device?
Dr Barbone: The VO 2 that I am showing, it is at three months VO 2 here, so it is very early. They go on to tolerate exercise very well. The data is insufficient at this point, but the overall rate of recovery I can testify is higher. But, yes, the numbers are those that I have shown.
